AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”

AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B

August 20, 2024 Shannon Young, Associate Editor/Senior Writer Views

A major hospital advocacy group recently urged congressional advisers to “carefully consider” the potential negative consequences of any new efforts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Site Footer Live